Prajakta B. KOTHAWADE, Kiran Bharat LOKHANDE, Kakumani Venkateswara SWAMY, Sohan S. CHITLANGE, Asha B. THOMAS

Novel nitrogen-containing heterocyclic compounds in GPR109A as an anti-hyperlipidemic: Homology modeling, docking, dynamic simulation studies

Niacin or nicotinic acid therapy leads to reduction of the level of Low-density Lipoprotein cholesterol(20-40%) with significant elevation of High-Density Lipopreoin cholesterol level (20-35%). From research, it was said that Nicotinic acid might exert its positive action by activating the G-protein-coupled receptor (GPCR) which is found on adipocytes. GPR109A (family of GPCR) receptor was important for nicotinic acid (niacin) for its anti-lipolytic effects. As GPR109A is a targeted receptor for the treatment of dyslipidemia, its structural analysis needs to be elucidated. But the Protein 3D structure of target was not available at Protein Data Bank (PDB), so we have generated its structure through homology modeling and validation was carried out. Screening of top lead molecules with the help of various computational approaches like molecular-docking and molecular dynamic (MD) simulations studies with different online tools were carried out. The docking results showed that the lead compound 2B [(R)-methyl 2-(2- (1H-indol-3-yl) acetamido)-3-(1H-indol-3-yl) propionate] revealed significant binding energy value (-30.54 kcal/mol) as that with the nicotinic acid which is a standard drug (-17.68 kcal/mol). In addition to that, Molecular-Dynamic (MD) simulations analysis proved that compound 2B has lesser variations throughout the simulation period as represented by the root-mean-square deviation (RMSD) and root-mean-square fluctuation (RMSF) graphs. Current in silico study describes the modeling of novel heterocyclic compounds as antihyperlipidemic drugs for the treatment of dyslipidemia. This study also describes a deeper idea about the structural information of the lead compound 2B and its entire molecular interactions against GPCR109A and provides a hypothetical guideline to utilize this compound as an antihyperlipidemic for the treatment of dyslipidemia.

PDF

___

[1] Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem. 1995; 54(2): 558–559. [CrossRef]
[2] Carlson LA, Oro L. The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympa-thicolysis. Acta Med Scand. 1962; 172: 641–645. [CrossRef]
[3] Blum CB, Levy RI, Eisenberg S, Hall M, Goebel RH, Berman M. High density lipoprotein metabolism in man. J Clin Invest. 1977; 60(4): 795–807. [CrossRef]
[4] Olsson AG. Principles and Treatment of Lipoprotein Disorders. Handbook of Experi-mental Pharmacology. 1994; 109: 349–400. [CrossRef
[6] Aktories K, Schultz G, Jakobs KH. Inactivation of the guanine nucleotide regulatory site mediating inhibition of the adeny-late cyclase in hamster adipocytes. Naunyn-Schmiedeberg’s Arch Pharmacol. 1982; 321(4): 247–252.
[7] Tornvall P, Hamsten A, Johansson J, Carlson LA. Normalisation of the composition of very low density lipoprotein in hypertriglyceridemia by nicotinic acid. Atherosclerosis. 1990; 84(2-3): 219–227. [CrossRef]
[8] Soga T, Kamohara M, Takasaki J, Matsumoto S, Saito T, Ohishi T, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun. 2003; 303(1): 364–369. [CrossRef]
[9] Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nat Med. 2003; 9(3): 352–355. [CrossRef]
[10] Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003; 278(11): 9869–9874. [CrossRef]
[11] Lee DK, Nguyen T, Lynch KR, Cheng R, Vanti WB, Arkhitko O, et al. Discovery and mapping of ten novel G. Protein coupled receptor genes. Gene. 2001; 275(1): 83–91. [CrossRef]
[12] Teller DC, Okada T, Behnke CA, Palczewski K, Stenkamp RE, , Advances in determination of a high-resolution three-dimensional structure of rhodopsin. A model of G-protein-coupled receptors (GPCRs). Biochem. 2001; 40(26): 7761–7772. [CrossRef]
[13] Tanura s, Jens L, Jukka K, Gerd K, Stefan O. Characterization of Determinants of Ligand Binding to the Nicotinic Acid Receptor GPR109A (HM74A/PUMA-G). Mol Pharmacol 2005; 68(5): 1271–1280. [CrossRef]
[14] Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000; 28(1): 235–242. [CrossRef]
[15] Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR. 1996; 8(4): 477–486. [CrossRef]
[16] Shepherd J, Packard CJ, Patsch JR, Gotto AM, Taunton OD. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 1979; 63(5): 858– 867. [CrossRef]
[17] Goldsmith GA, Cordill S. The vasodilating effects of nicotinic acid (relation to metabolic rate and body temperature). Am J Med Sci. 1943; 205: 204–208.
[18] Benyo Z, Gille A, Kero J, Csiky M, Suchánková MC, Nüsing RM, et al. GPR109A (HM74A/PUMA-G) mediates nicotinic acid induced flushing. J Clin Invest. 2005; 115(12): 3634–3640. [CrossRef]
[19] Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018; 46 (W1): W296–W303. [CrossRef]
[20] Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK - a program to check the stereochemical quality of protein structures. J App Cryst. 1993; 26(2): 283–291. [CrossRef]
[21] Markus W, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007; 35: W407–W410. [CrossRef]
[22] Eisenberg D, Lüthy R, Bowie JU. VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol. 1997; 277: 396–404. [CrossRef]
[23] Roman AL. PDBsum new things. Nucleic Acids Res. 2009; 37(1): D355–D359. [CrossRef]
[24] Pandy-Szekeres G, Munk C, Tsonkov TM, Mordalski S, Harpsøe K, Hauser AS, Bojarski AJ. Gloriam DE. GPCRdb in 2018: adding GPCR structure models and ligands. Nucleic Acids Res. 2018; 46 (D1): D440–D448. [CrossRef]
[25] Schrodinger Release 2018-1: Maestro. Schrodinger, LLC, New York, NY, 2018.
[26] DuBay KH, Hall ML, Hughes TF, Wu C, Reichman DR, Friesner RA. Accurate Force Field Development for Modeling Conjugated Polymers. J Chem Theory Comput. 2012; 8(11): 4556–4569. [CrossRef]
[27] Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol. 1996; 261(3): 470–489. [CrossRef]
[28] Kevin J, Bowers C Edmond, Huafeng X, Ron OD, Michael PE, Brent AG, et al. . Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters. Proceedings of the ACM/IEEE Conference on Supercomputing (SC06) 2006. [CrossRef]
[29] Chen C, Huang H, Wu CH. Protein Bioinformatics Databases and Resources Methods. Mol Biol. 2017;1558: 3–39.[CrossRef]
[30] McGinnis S, Madden TL. BLAST: at the core of a powerful and diverse set of sequence analysis tools. Nucleic Acids Res. 2004; 32:W20–W25. [CrossRef]
[31] Zhang D, Gao ZG, Zhang K, Kiselev E, Crane S, Wang J, et al. Two disparate ligand-binding sites in the human P2Y1 receptor. Nature. 2015; 520(7547): 317–321. [CrossRef]
[32] Schrodinger Release 2018-1: Protein Preparation Wizard. Schrodinger, LLC, New York, NY, 2018.
[33] ChemAxon L., Marvin Sketch 5114 (2012).
[34] Badry DB, Maxim T, Ruben A, Charles LB. Comparative study of several algorithms for flexible ligand docking. J Comput Aid Mol Des. 2003; 17(11): 755–763. [CrossRef]
[35] Schrodinger Release 2017-4: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY. MaestroDesmond Interoperability Tools. Schrodinger, LLC, New York, NY, 2017